English | 简体中文 | 繁體中文 | 한국어
Share:
NOVA Chemicals Corporation to Offer $2,100 Million of Senior Notes

nova-chemicals_rgb

NOVA Chemicals Corporation, 1000 Seventh Avenue S.W., Calgary, Alberta, Canada T2P 5L5
www.novachemicals.com | 403.750.3600 tel | 403.269.7410 fax

Calgary, Alberta (May 19, 2017) - NOVA Chemicals Corporation ("NOVA Chemicals") announced today that it intends to offer $2,100 million of senior notes, together with cash on hand, to fund its previously announced acquisition of Williams Partners L.P.'s 88.46% interest in the Geismar Olefins Plant, adjacent land, and interest in the Ethylene Trading Hub in Mt. Belvieu, Texas, and to pay fees and expenses relating to the transaction and this offering.

Barclays Capital, Inc. and HSBC Securities (USA) Inc. are acting as joint active bookrunners and TD Securities (USA) LLC, RBC Capital Markets, LLC and Scotia Capital (USA) Inc. are acting as joint bookrunners.

The senior notes will be issued in reliance on the exemption from the registration requirements provided by Rule 144A and Regulation S of the United States Securities Act of 1933, as amended (the "Securities Act"). None of the senior notes have been registered under the Securities Act or the laws of any state or other jurisdiction and may not be offered or sold in the United States absent registration or an applicable exemption from the registration requirements of the Securities Act and applicable state securities laws.

This news release does not constitute an offer to sell or the solicitation of an offer to buy any security, nor will there be any sale of any security in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state other jurisdiction.

About NOVA Chemicals
NOVA Chemicals develops and manufactures chemicals and plastic resins that make everyday life safer, healthier and easier. Our employees work to ensure health, safety, security and environmental stewardship through our commitment to sustainability and Responsible Care®. NOVA Chemicals, headquartered in Calgary, Alberta, Canada, is wholly-owned ultimately by Mubadala Investment Company of the Emirate of Abu Dhabi, United Arab Emirates.

###

For further information please contact:
NOVA Chemicals - Media Inquiries
Mark Horner
Director, Corporate Communications
e-mail: mark.horner@novachem.com

NOVA Chemicals - Investor Inquiries
Tracey Simpson
Leader, External Financial Reporting
e-mail: tracey.simpson@novachem.com

The NOVA Chemicals logo is a registered trademark of NOVA Brands Ltd.; authorized use.
Responsible Care is a registered trademark of the Chemistry Industry Association of Canada





This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: NOVA Chemicals Corporation via Globenewswire

Copyright © Thomson Reuters 2018. All rights reserved.
Press Releases
Orion to sell its Orion Diagnostica division - Due to the transaction Orion updates its outlook  
Apr 21, 2018 00:30 ET
Helsinn Group announces the FDA approval of the IV formulation of AKYNZEO® (fosnetupitant/ palonosetron) in the United States  
Apr 20, 2018 21:33 ET
BOURBON: Positive progress in negotiations with lenders  
Apr 20, 2018 18:30 ET
Hubbell Incorporated Declares Regular Quarterly Dividend  
Apr 20, 2018 16:01 ET
Helsinn Group announces the FDA approval of the IV formulation of AKYNZEO® (fosnetupitant/ palonosetron) in the United States  
Apr 20, 2018 15:23 ET
Heineken Holding N.V. - Amendments to the Articles of Association  
Apr 20, 2018 15:18 ET
Lubrizol Presents Estane® TPU and Other Innovations for Consumer, Industrial, Footwear and Electronics Applications at Chinaplas 2018  
Apr 20, 2018 12:03 ET
Lipotec Active Ingredients Becomes Umbrella Brand  
Apr 19, 2018 23:43 ET
LEH PHARMA LTD.: Company Update  
Apr 18, 2018 19:34 ET
Tusk Therapeutics presents data on to its anti-CD25 programme at AACR Annual Meeting 2018  
Apr 18, 2018 19:33 ET
More News >>
Copyright © 2018 ACN Newswire - Asia Corporate News Network
Home | About us | Services | Partners | Events | Login | Contact us | Privacy Policy | Terms of Use | RSS
US: +1 800 291 0906 | Beijing: +86 10 8405 3688 | Hong Kong: +852 2217 2912 | Singapore: +65 6304 8926 | Tokyo: +81 3 5791 1818

Connect With us: